According to the instructions for the Nomination Committee of
Immunovia AB (Publ) that were adopted at the Annual General Meeting
on May 6, 2021, the Nomination
Committee shall consist of four members.
LUND, Sweden, Oct. 25, 2021 /PRNewswire/ -- The Nomination
Committee, which is to be appointed for the period until a new
Nomination Committee is appointed, shall consist of four members,
of which three will be appointed by the Company's three largest
shareholders in terms of voting, and the fourth shall be the
Chairman of the Board. In the event that the Chairman of the Board
is one of the three largest shareholders, he shall, in his/her
capacity as shareholder, make his seat available and the next
shareholder shall be offered the right to appoint a member to the
Nomination Committee. The Chairman of the Board shall, as soon as
reasonably practicable after the end of the third quarter, contact
the three largest shareholders registered in the share register
kept by Euroclear Sweden AB at this time in an appropriate manner
and request them to, within a reasonable time, may not exceed 30
days, in writing to the Nomination Committee name the person the
shareholder wishes to appoint as a member of the Nomination
Committee. If one of the three largest shareholders do not wish to
exercise his right to appoint a member of the Nomination Committee,
the next shareholder shall in turn be offered the right to appoint
a member of the Nomination Committee. In the event that several
shareholders waive their right to appoint members of the Nomination
Committee, the Chairman of the Board shall not have to contact more
than eight shareholders, unless it is necessary to convene a
Nomination Committee consisting of at least three members.
Unless otherwise agreed between the members, the member
appointed by the largest shareholder in terms of number of votes
shall be appointed chairman of the nomination committee. The
Chairman of the Board or another Board member shall never be the
Chairman of the Nomination Committee.
Based on the above, the Nomination Committee for the 2022 Annual
General Meeting has been determined to consist of the following
persons who together represent 21,3 percent of the number of shares
and votes in the company as of September 30,
2021:
- Sara Ek, representing
Sara Ek,
- Carl Borrebaeck representing Carl Borrebaeck, Chairman of the
Board
- Peter Lindvall representing
Mikael Löfman; and
- Mats Leifland, representing Mats
Ohlin
The Nomination Committee's proposal will be presented in the
notice convening the Annual General Meeting 2022 and at the
company's website, www.immunovia.com.
Shareholders who wish to submit proposals to the Nomination
Committee are welcome to contact the Nomination Committee at the
company's address. In order for the Nomination Committee to be able
to consider a proposal, the proposal must have been received in
good time before the Annual General Meeting, but no later than
31 January 2022.
For more information, please contact:
Patrik Dahlen, CEO
Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
PanDIA-1.
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com. The European
launch plan will be communicated during the second half of
2021.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/nomination-committee-appointed-for-the-2022-annual-general-meeting-of-immunovia-ab--publ-,c3439164
The following files are available for download:
https://mb.cision.com/Main/13121/3439164/1485526.pdf
|
Press release
(PDF)
|